D.E. Shaw & Co
LKFT

D.E. Shaw & Co’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

D.E. Shaw & Co’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-9,200
Closed -$507K – 5674
2021
Q4 		$507K Hold
9,200
– – ﹤0.01% 4394
2021
Q3 		$484K Hold
9,200
– – ﹤0.01% 4099
2021
Q2 		$634K Buy
+9,200
New +$702K ﹤0.01% 3900

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

D.E. Shaw & Co's LKFT Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 8.3% in Q2 2026, selling an estimated $507K and leaving 197,844 shares worth $5.93M. The position accounts for ﹤0.01% of the portfolio, ranked #2263.

D.E. Shaw & Co first reported a position in LKFT in Q3 2018 and has held it in 27 quarters since. The position peaked at $8.99M in Q4 2025. 77 funds tracked by Wall St. Rank hold LKFT as of Q2 2026.

  • D.E. Shaw & Co held 197,844 shares of Lakefront Biotherapeutics American Depositary Shares worth $5.93M as of Q2 2026.
  • D.E. Shaw & Co sold 17,874 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2026, an estimated $507K.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2263 holding.
  • D.E. Shaw & Co first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2018 and has held it in 27 quarters since.
  • D.E. Shaw & Co's Lakefront Biotherapeutics American Depositary Shares position peaked at $8.99M in Q4 2025.
  • 77 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.